Page:  1  2  3  4 INOmax Improves Oxygenation Efficacy of INOmax in Hypoxic Respiratory Failure (HRF) proven in well-controlled clinical trials •   INOmax significantly improves oxygenation, as measured by partial pressure of arterial oxygen (PaO2) and oxygenation index (OI).1,2    •   INOmax, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.2   Significantly greater PaO2 increase in 30 minutes3       Significantly greater change in OI in 30 minutes3   •   The recommended dose of INOmax is 20 parts per million (ppm). Treatment should be maintained up to 14 days or until the underlying oxygen desaturation has resolved and the neonate is ready to be weaned from INOmax therapy. In the CINRGI trial, patients whose oxygenation improved with 20 ppm were dose-reduced to 5 ppm as tolerated at the end of 4 hours of treatment. Doses above 20 ppm ordinarily should not be used because of the increased risk of methemoglobinemia and elevated nitrogen dioxide (NO2) levels.2

Information intended for the United States. For information outside the US CLICK HERE

For Terms of Use, CLICK HERE

© 2007-08 Ikaria^®.